Inozyme Pharma Reports First Quarter 2022 Financial Results and Provides Business HighlightsGlobeNewsWire • 05/10/22
Inozyme Pharma Announces $73 Million Underwritten Offering Priced At-the-MarketGlobeNewsWire • 04/14/22
Inozyme Pharma Provides Update for Phase 1/2 Clinical Trials in ABCC6 Deficiency and ENPP1 DeficiencyGlobeNewsWire • 04/12/22
Inozyme Pharma to Present at the 21st Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/06/22
Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Patients with ENPP1 DeficiencyGlobeNewsWire • 04/04/22
Inozyme Pharma Reports Full Year 2021 Financial Results and Provides Business HighlightsGlobeNewsWire • 03/15/22
Inozyme Pharma Announces Dosing of First Patient in First-in-Human Clinical Trial of INZ-701 in Patients with ENPP1 DeficiencyGlobeNewsWire • 11/15/21
Wall Street Analysts Believe Inozyme Pharma, Inc. (INZY) Could Rally 257%: Here's is How to TradeZacks Investment Research • 11/12/21
Inozyme Pharma Announces Presentation of Data from ENPP1 Deficiency Development Program at the ASBMR 2021 Annual MeetingGlobeNewsWire • 10/04/21
Inozyme Pharma to Present at the 2021 Cantor Virtual Global Healthcare ConferenceGlobeNewsWire • 09/22/21
Inozyme Pharma Reports Q2 2021 Financial Results and Provides Business HighlightsGlobeNewsWire • 08/11/21
Inozyme Pharma to Participate in 2021 Wedbush PacGrow Healthcare Virtual ConferenceGlobeNewsWire • 08/04/21
Inozyme Pharma Receives Orphan Drug Designation for INZ-701 from the European Medicines Agency for the Treatment of ABCC6 DeficiencyGlobeNewsWire • 07/21/21
Inozyme Pharma Announces Appointment of Gayle Gironda as Senior Vice President, Human ResourcesGlobeNewsWire • 07/13/21
Inozyme Announces Acceptance of First European Clinical Trial Application for Phase 1/2 Clinical Trial of INZ-701 in ABCC6 DeficiencyGlobeNewsWire • 06/09/21
Inozyme Pharma Reports Q1 2021 Financial Results and Provides Business HighlightsGlobeNewsWire • 05/12/21